Guido J. R. Zaman
Guido J. R. Zaman has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Jos de Man
25 shared publicationsJoost C.M. Uitdehaag
20 shared publicationsJeroen A.D.M. de Roos
17 shared publicationsMartine B.W. Prinsen
17 shared publications- Rogier C. Buijsman
Netherlands Translational Research Center, Oss, Netherlands
13 shared publications Nicole Willemsen-Seegers
12 shared publications
Latest Publications
- Open Access
- 4 July 2025
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 88 (7) , 1766-1771
Synthesis and Absolute Configuration of the Sesquiterpene Lactone EPD, a Natural Product with Broad Antitumor Cell Activity via a Unique Mechanism of Action
The sesquiterpene lactone eremophila-1(10),11(13)-dien-12,8β-olide (EPD), isolated from leaves of the Calomeria amaranthoides plant, has shown cytotoxic activity on human cancer cell lines, including ovarian cancer-derived cells. To enable further preclinical investigation of EPD as a potential anticancer agent, a chemical synthetic route was developed. NMR and HPLC analysis confirmed that synthetic EPD was identical to natural EPD. The absolute configuration of EPD was established by 3D electron diffraction of a solid precursor. Parallel testing on a panel of more than one hundred human cancer cell lines derived from diverse solid tumors and hematologic malignancies revealed an almost identical profile for synthetic and natural EPD. Furthermore, this profile was unique among 248 anticancer agents that have been profiled on the same panel. These studies merit further investigation of EPD and synthetic analogs for the development of novel anticancer therapies for cancers with high unmet need, including ovarian cancer.
- 4 July 2025
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 88 (7) , 1766-1771
Open AccessSynthesis and Absolute Configuration of the Sesquiterpene Lactone EPD, a Natural Product with Broad Antitumor Cell Activity via a Unique Mechanism of Action
The sesquiterpene lactone eremophila-1(10),11(13)-dien-12,8β-olide (EPD), isolated from leaves of the Calomeria amaranthoides plant, has shown cytotoxic activity on human cancer cell lines, including ovarian cancer-derived cells. To enable further preclinical investigation of EPD as a potential anticancer agent, a chemical synthetic route was developed. NMR and HPLC analysis confirmed that synthetic EPD was identical to natural EPD. The absolute configuration of EPD was established by 3D electron diffraction of a solid precursor. Parallel testing on a panel of more than one hundred human cancer cell lines derived from diverse solid tumors and hematologic malignancies revealed an almost identical profile for synthetic and natural EPD. Furthermore, this profile was unique among 248 anticancer agents that have been profiled on the same panel. These studies merit further investigation of EPD and synthetic analogs for the development of novel anticancer therapies for cancers with high unmet need, including ovarian cancer.
- Open Access
- 4 March 2024
- Published by Elsevier in Mucosal Immunology
- Vol. 17 (3) , 346-358
The bacterial lysate OM-85 engages Toll-like receptors 2 and 4 triggering an immunomodulatory gene signature in human myeloid cells
- 4 March 2024
- Published by Elsevier in Mucosal Immunology
- Vol. 17 (3) , 346-358
Open AccessThe bacterial lysate OM-85 engages Toll-like receptors 2 and 4 triggering an immunomodulatory gene signature in human myeloid cells
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers